Vice President Of Clinical Diagnostics
CurrentOxford Biodynamics is focused on the clinical adoption of our flagship platform, the EpiSwitchⓇ Checkpoint inhibitor Response Test (CiRT), a blood test that predicts how a patient will respond to immune checkpoint inhibitor (ICI) immunotherapies during anti-cancer care, as well the company's suite of therapeutic response, disease prognostication and early cancer detection assays.